Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative
Gregg C. Fonarow(UCLA Medical Center), Lee H. Schwamm(Yale University), Eric E. Smith(University of Calgary), Ying Xian(Indianapolis Zoo), Mathew J. Reeves(Michigan State University), Eric D. Peterson(The University of Texas Southwestern Medical Center), Jeffrey L. Saver(University of California, Los Angeles), Deepak L. Bhatt(Mount Sinai Hospital), Xin Zhao, Adrian F. Hernandez(Duke University)
Cited by 563
Related Papers
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
|New England Journal of Medicine|2015|6k
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
|New England Journal of Medicine|2017|5.5k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k